N Anthony Coles Sells 25,000 Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Stock

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CEREGet Free Report) Director N Anthony Coles sold 25,000 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $41.18, for a total value of $1,029,500.00. Following the transaction, the director now directly owns 25,928 shares in the company, valued at $1,067,715.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

N Anthony Coles also recently made the following trade(s):

  • On Friday, May 10th, N Anthony Coles sold 50,000 shares of Cerevel Therapeutics stock. The stock was sold at an average price of $42.10, for a total transaction of $2,105,000.00.

Cerevel Therapeutics Trading Down 2.3 %

Shares of NASDAQ:CERE opened at $40.30 on Friday. The company has a market capitalization of $7.34 billion, a PE ratio of -14.76 and a beta of 1.40. Cerevel Therapeutics Holdings, Inc. has a 12-month low of $19.59 and a 12-month high of $43.59. The business has a 50 day moving average of $41.43 and a two-hundred day moving average of $41.81. The company has a current ratio of 10.22, a quick ratio of 10.22 and a debt-to-equity ratio of 0.60.

Cerevel Therapeutics (NASDAQ:CEREGet Free Report) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.12). As a group, analysts forecast that Cerevel Therapeutics Holdings, Inc. will post -2.59 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Headlands Technologies LLC acquired a new position in Cerevel Therapeutics during the first quarter worth $26,000. Pacific Capital Wealth Advisors Inc. purchased a new stake in Cerevel Therapeutics in the fourth quarter valued at $71,000. Centaurus Financial Inc. purchased a new stake in shares of Cerevel Therapeutics in the 4th quarter valued at approximately $119,000. PNC Financial Services Group Inc. boosted its position in shares of Cerevel Therapeutics by 68.5% during the third quarter. PNC Financial Services Group Inc. now owns 9,506 shares of the biotechnology company’s stock worth $208,000 after buying an additional 3,866 shares during the period. Finally, GAM Holding AG acquired a new position in shares of Cerevel Therapeutics in the fourth quarter valued at approximately $212,000. 87.73% of the stock is currently owned by institutional investors and hedge funds.

About Cerevel Therapeutics

(Get Free Report)

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.

Further Reading

Insider Buying and Selling by Quarter for Cerevel Therapeutics (NASDAQ:CERE)

Receive News & Ratings for Cerevel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerevel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.